. 2019 Aug 5;38:338. doi: 10.1186/s13046-019-1336-3

Table 1.

Analyses of time to disease progression in advance GC patients under the treatment of oxaliplatin

Factors	N	Univariate analysis		Multivariate analysis
Factors	N	HR (95% CI)	P	HR (95% CI)	P
Gender
Female	34	1.140 (0.643–2.022)	0.653
Male	87	1.140 (0.643–2.022)	0.653
Age
< 60	51	1.345 (0.799–2.264)	0.265
≥ 60	70	1.345 (0.799–2.264)	0.265
Stage
I & II	61	2.776 (1.627–4.734)	< 0.001	2.106 (1.221–3.631)	0.007
III & IV	60	2.776 (1.627–4.734)	< 0.001	2.106 (1.221–3.631)	0.007
Metastasis
No	45	3.978 (2.062–7.675)	< 0.001	3.534 (1.818–6.868)	< 0.001
Yes	76	3.978 (2.062–7.675)	< 0.001	3.534 (1.818–6.868)	< 0.001
Type
Diffuse	105	0.658 (0.283–1.571)	0.331
Intestinal	16	0.658 (0.283–1.571)	0.331
GKN2
Low (− & +)	87	0.544 (0.215–0.798)	0.008	0.464 (0.239–0.901)	0.023
High (++&+++)	34	0.544 (0.215–0.798)	0.008	0.464 (0.239–0.901)	0.023

Staining intensity, negative: -, weak positive: +, moderate positive: ++, strong positive: +++